Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial
Top Cited Papers
- 1 December 2001
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 358 (9296), 1855-1863
- https://doi.org/10.1016/s0140-6736(01)06887-8
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trialThe Lancet, 2001
- Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction. A phase II dose escalation, randomized, double-blind studyPublished by Oxford University Press (OUP) ,2000
- Thrombin Generation, Inhibition and Clinical Outcomes in Patients With Acute Myocardial Infarction Treated With Thrombolytic Therapy and Heparin: Results From the GUSTO-I TrialJournal of the American College of Cardiology, 1998
- A Comparison of Reteplase with Alteplase for Acute Myocardial InfarctionNew England Journal of Medicine, 1997
- Selection of thrombolytic therapy for individual patients: Development of a clinical modelAmerican Heart Journal, 1997
- Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial InfarctionNew England Journal of Medicine, 1997
- Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinaseJournal of the American College of Cardiology, 1994
- The Effects of Tissue Plasminogen Activator, Streptokinase, or Both on Coronary-Artery Patency, Ventricular Function, and Survival after Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.Journal of Clinical Investigation, 1990